![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: KRT2 |
Gene summary for KRT2 |
![]() |
Gene information | Species | Human | Gene symbol | KRT2 | Gene ID | 3849 |
Gene name | keratin 2 | |
Gene Alias | CK-2e | |
Cytomap | 12q13.13 | |
Gene Type | protein-coding | GO ID | GO:0001667 | UniProtAcc | P35908 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3849 | KRT2 | P4_S8_cSCC | Human | Skin | cSCC | 1.75e-20 | 3.71e-01 | -0.3095 |
3849 | KRT2 | cSCC_p11 | Human | Skin | cSCC | 8.41e-11 | 2.91e-01 | -0.2102 |
3849 | KRT2 | cSCC_p3 | Human | Skin | cSCC | 5.59e-19 | 6.90e-01 | -0.2085 |
3849 | KRT2 | cSCC_p7 | Human | Skin | cSCC | 1.05e-04 | 3.65e-01 | -0.2332 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Skin | ![]() | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma | ||
SCCIS:squamous cell carcinoma in situ |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003166931 | Stomach | SIM | cellular response to nutrient levels | 18/708 | 215/18723 | 1.40e-03 | 1.70e-02 | 18 |
Page: 1 2 3 4 5 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KRT2 | SNV | Missense_Mutation | rs371361222 | c.700N>A | p.Asp234Asn | p.D234N | P35908 | protein_coding | tolerated(0.5) | benign(0.058) | TCGA-A2-A04T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
KRT2 | SNV | Missense_Mutation | novel | c.347N>C | p.Gly116Ala | p.G116A | P35908 | protein_coding | tolerated(0.49) | benign(0.232) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
KRT2 | SNV | Missense_Mutation | rs137852629 | c.1459G>A | p.Glu487Lys | p.E487K | P35908 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KRT2 | SNV | Missense_Mutation | rs776596709 | c.986N>T | p.Thr329Ile | p.T329I | P35908 | protein_coding | deleterious(0) | benign(0.348) | TCGA-AO-A124-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
KRT2 | SNV | Missense_Mutation | rs182397714 | c.851N>T | p.Thr284Met | p.T284M | P35908 | protein_coding | tolerated(0.13) | probably_damaging(0.971) | TCGA-C8-A12W-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
KRT2 | SNV | Missense_Mutation | c.1171N>C | p.Glu391Gln | p.E391Q | P35908 | protein_coding | deleterious(0.04) | benign(0.417) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
KRT2 | SNV | Missense_Mutation | c.1020N>A | p.Ser340Arg | p.S340R | P35908 | protein_coding | deleterious(0) | possibly_damaging(0.9) | TCGA-JL-A3YW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
KRT2 | SNV | Missense_Mutation | novel | c.922N>G | p.Gln308Glu | p.Q308E | P35908 | protein_coding | tolerated(0.17) | benign(0.173) | TCGA-LL-A8F5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
KRT2 | deletion | Frame_Shift_Del | novel | c.146delN | p.Gly49ValfsTer87 | p.G49Vfs*87 | P35908 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
KRT2 | SNV | Missense_Mutation | novel | c.1558N>T | p.Gly520Cys | p.G520C | P35908 | protein_coding | deleterious(0.02) | possibly_damaging(0.52) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |